Addressing these limitations would be important to confidently progress the TRAILv modification of NK cells into in vivo assessment and subsequently clinical trials, as TRAIL in an attractive target due to its significant upregulation post-chemotherapy treatment in ovarian cancer patients [19]. This evidence concerns the gene TNFSF10 and ovarian carcinoma.